ARQT logo

ARQT
Arcutis Biotherapeutics Inc

2,507
Mkt Cap
$3.35B
Volume
2.59M
52W High
$30.01
52W Low
$10.21
PE Ratio
-83.19
ARQT Fundamentals
Price
$29.49
Prev Close
$27.33
Open
$27.15
50D MA
$21.59
Beta
1.35
Avg. Volume
2.52M
EPS (Annual)
-$1.16
P/B
22.44
Rev/Employee
$574,684.21
Loading...
Loading...
News
all
press releases
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
Zacks·2d ago
News Placeholder
More News
News Placeholder
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Zacks·2d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2d ago
News Placeholder
Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 12-Month High - What's Next?
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year High - What's Next...
MarketBeat·3d ago
News Placeholder
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Zacks·3d ago
News Placeholder
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Neha Krishnamohan Sells 40,504 Shares
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Neha Krishnamohan sold 40,504 shares of the business's stock in a transaction dated Thursday, November 13th. The shares were...
MarketBeat·3d ago
News Placeholder
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Zacks·4d ago
News Placeholder
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Zacks·4d ago
News Placeholder
Neha Krishnamohan Sells 40,504 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Neha Krishnamohan sold 40,504 shares of the firm's stock in a transaction on Thursday, November 13th. The stock was sold at an...
MarketBeat·4d ago
News Placeholder
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·5d ago

Latest ARQT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.